Stem cells increase in numbers in perinecrotic areas in human renal cancer.

Date publication

février 2015

Journal

Clinical cancer research : an official journal of the American Association for Cancer Research

Auteurs

Membres identifiés du Cancéropôle Est :
Pr FEUGEAS Jean-Paul

Tous les auteurs :
Varna M, Gapihan G, Feugeas JP, Ratajczak P, Tan S, Ferreira I, Leboeuf C, Setterblad N, Duval A, Verine J, Germain S, Mongiat-Artus P, Janin A, Bousquet G

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/25501128

Résumé

Developing strategies to overcome resistance to sunitinib is a major challenge in human renal cell carcinoma (RCC). We hypothesized that sunitinib-induced tumor necrosis-associated hypoxia could interact with renal cancer stem cells in patients with metastatic RCC.

Mots clés

Animals, Antineoplastic Agents, therapeutic use, Carcinoma, Renal Cell, drug therapy, Drug Resistance, Neoplasm, physiology, Humans, Indoles, therapeutic use, Kidney Neoplasms, drug therapy, Mice, Mice, Nude, Necrosis, Neoplastic Stem Cells, drug effects, Pyrroles, therapeutic use, Sunitinib, Xenograft Model Antitumor Assays

Référence

Clin. Cancer Res.. 2015 Feb 15;21(4):916-24